LIST OF TABLES
UU
TABLE 1 MERCK KGAA, R&D ACTIVITIES
TABLE 2 LONZA, R&D ACTIVITIES
TABLE 3 THERMO FISHER SCIENTIFIC INC, R&D ACTIVITIES
TABLE 4 F. HOFFMANN-LA ROCHE LTD, R&D ACTIVITIES
TABLE 5 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 6 NORTH AMERICA KITS & REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 7 NORTH AMERICA KITS AND REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 8 NORTH AMERICA INSTRUMENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 9 NORTH AMERICA SERVICES IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 10 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUES, 2017-2026 (USD MILLION)
TABLE 11 NORTH AMERICA MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 12 NORTH AMERICA POLYMERASE CHAIN REACTION IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 13 NORTH AMERICA ELISA IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 14 NORTH AMERICA DNA STAINING/INDIRECT ASSAY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 15 NORTH AMERICA ENZYMATIC METHODS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 16 NORTH AMERICA OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 17 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2026 (USD MILLION)
TABLE 18 NORTH AMERICA RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 19 NORTH AMERICA RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 20 NORTH AMERICA RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 21 NORTH AMERICA UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 22 NORTH AMERICA UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 23 NORTH AMERICA UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 24 NORTH AMERICA GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 25 NORTH AMERICA GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 26 NORTH AMERICA GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 27 NORTH AMERICA CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 28 NORTH AMERICA CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 29 NORTH AMERICA CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 30 NORTH AMERICA MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 31 NORTH AMERICA MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 32 NORTH AMERICA MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 33 NORTH AMERICA OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 34 NORTH AMERICA OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 35 NORTH AMERICA OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 36 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2017-2026 (USD MILLION)
TABLE 37 NORTH AMERICA HOSPITALS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 38 NORTH AMERICA DIAGNOSTIC LABORATORIES IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 39 NORTH AMERICA KITS & REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY REGION, 2017-2026 (USD MILLION)
TABLE 40 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
TABLE 41 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 42 NORTH AMERICA KITS AND REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 43 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 44 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2026 (USD MILLION)
TABLE 45 NORTH AMERICA UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 46 NORTH AMERICA UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 47 NORTH AMERICA RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 48 NORTH AMERICA RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 49 NORTH AMERICA CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 50 NORTH AMERICA CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 51 NORTH AMERICA MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 52 NORTH AMERICA MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 53 NORTH AMERICA GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 54 NORTH AMERICA GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 55 NORTH AMERICA OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 56 NORTH AMERICA OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 57 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2017-2026 (USD MILLION)
TABLE 58 U.S. MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 59 U.S. KITS AND REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 60 U.S. MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 61 U.S. MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2026 (USD MILLION)
TABLE 62 U.S. UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 63 U.S. UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 64 U.S. RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 65 U.S. RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 66 U.S. CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 67 U.S. CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 68 U.S. MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 69 U.S. MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 70 U.S. GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 71 U.S. GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 72 U.S. OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 73 U.S. OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 74 U.S. MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2017-2026 (USD MILLION)
TABLE 75 CANADA MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 76 CANADA KITS AND REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 77 CANADA MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 78 CANADA MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2026 (USD MILLION)
TABLE 79 CANADA UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 80 CANADA UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 81 CANADA RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 82 CANADA RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 83 CANADA CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 84 CANADA CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 85 CANADA MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 86 CANADA MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 87 CANADA GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 88 CANADA GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 89 CANADA OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 90 CANADA OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 91 CANADA MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2017-2026 (USD MILLION)
TABLE 92 MEXICO MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 93 MEXICO KITS AND REAGENTS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS, 2017-2026 (USD MILLION)
TABLE 94 MEXICO MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 95 MEXICO MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA, 2017-2026 (USD MILLION)
TABLE 96 MEXICO UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 97 MEXICO UROGENITAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 98 MEXICO RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 99 MEXICO RESPIRATORY IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 100 MEXICO CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 101 MEXICO CARDIOVASCULAR IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 102 MEXICO MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 103 MEXICO MUSCULOSKELETAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 104 MEXICO GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 105 MEXICO GASTROINTESTINAL IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 106 MEXICO OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY CAUSATIVE AGENT, 2017-2026 (USD MILLION)
TABLE 107 MEXICO OTHERS IN MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUE, 2017-2026 (USD MILLION)
TABLE 108 MEXICO MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER, 2017-2026 (USD MILLION)

LIST OF FIGURE

LIST OF FIGURES

FIGURE 1 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: DATA VALIDATION MODEL
FIGURE 3 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: NORTH AMERICA VS REGIONAL
FIGURE 5 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 9 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET
FIGURE 10 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE INCREASING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2019 TO 2026
FIGURE 11 INCREASING CASES OF MYCOPLASMA INFECTIONS AND TECHNOLOGIAL ADVANCEMENTS IN THE IDENTIFICATION TECHNIQUES ARE EXPECTED TO DRIVE THE NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET IN THE FORECAST PERIOD OF 2019 TO 2026
FIGURE 12 KITS & REAGENTS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET IN THE FORECAST PERIOD OF 2019 & 2026
FIGURE 13 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY TYPE, 2018
FIGURE 14 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY TECHNIQUES, 2018
FIGURE 15 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY DISEASE AREA, 2018
FIGURE 16 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY END USER, 2018
FIGURE 17 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: SNAPSHOT (2018)
FIGURE 18 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2018)
FIGURE 19 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2019 & 2026)
FIGURE 20 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY COUNTRY (2018 & 2026)
FIGURE 21 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: BY PRODUCTS (2019-2026)
FIGURE 22 NORTH AMERICA MYCOPLASMA TESTING IN CLINICAL MARKET: COMPANY SHARE 2018 (%)